Clinical Trial Update: A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term treatment and retreatment of lower-extremity diabetic ulcers with REGRANEX was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcer

Drugs mentioned

• Regranex (becaplermin)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Foot Ulcer, Diabetic Foot | Phase 3 | Status: TERMINATED